Skip to main content

Advertisement

Table 5 The evaluations of prognostic factors other than the presence of pneumothorax by the log-rank test

From: Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

  Progression-free survival (PFS)   Overall survival (OS)  
Variants n Hazard ratio (95 % CI) p-value Hazard ratio (95 % CI) p-value
Age ≥ 60 yo 19 0.64 (0.33–1.25) 0.19 0.88 (0.40–1.92) 0.74
Male gender 30 1.01 (0.55–1.85) 0.99 1.43 (0.69–2.96) 0.34
Synovial sarcoma 9 0.57 (0.24–1.35) 0.17 0.58 (0.20–1.66) 0.31
Hypertension+ 10 0.44 (0.17–1.13) 0.09 1.15 (0.43–3.03) 0.79
Smoking history+ 20 0.96 (0.51–1.80) 0.89 1.41 (0.67–2.94) 0.36
lung lesion+ 41 1.18 (0.59–2.35) 0.64 2.02 (0.77–5.30) 0.15
Number of lung lesions ≥2 35 0.96 (0.52–1.78) 0.90 1.06 (0.497–2.279) 0.87
Maximum diameter of lung lesions ≥ 30 mm 21 1.37 (0.75–2.51) 0.30 1.40 (0.685–2.878) 0.36